Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420027 | 0.85 | — | — | |
| SCHEMBL10254196 | 0.79 | HRH3 (0.35) | HRH3NPC1RAB9AOPRD1KDM4E | |
| SCHEMBL9957046 | 0.78 | POLB (0.38) | HRH3KDM4EALDH1A1 | |
| SCHEMBL9957528 | 0.78 | HTT (0.40) | KDM4EALDH1A1 | |
| SCHEMBL341318 | 0.77 | SMN1; SMN2 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL9372265 | 0.76 | HSD17B10 (0.40) | GAA | |
| SCHEMBL15541721 | 0.75 | SMN1; SMN2 (0.38) | HRH3ALDH1A1GAA | |
| SCHEMBL342302 | 0.75 | SMN1; SMN2 (0.38) | HRH3ALDH1A1GAA | |
| SCHEMBL10464172 | 0.74 | HRH3 (0.33) | HRH3OPRD1 | |
| SCHEMBL10464174 | 0.74 | HRH3 (0.33) | HRH3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0289746-B1 | 1,4-Dihydropyridine derivatives and pharmaceutical composition thereof | KYOTO PHARMA IND (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-4937242-A | CALCIUM ANTAGONISTS | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-06-26 | — | — | US | disclosed |